Issue of Shares and Total Voting Rights
Updated : 07:00
Issue of New Ordinary Shares to NHS Trusts and Total Voting Rights
Oxford, U.K. 16 April 2021: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the UK Clinical AI company, today announces that it has issued a total of 5,714,284 new ordinary shares of ten pence nominal value ("New Ordinary Shares") to Hampshire Hospitals NHS Foundation Trust. Milton Keynes University Hospital NHS Foundation Trust, Somerset NHS Foundation Trust and The Royal Wolverhampton NHS Trust in four equal allotments of 1,428,571 New Ordinary Shares.
These New Ordinary Shares have been issued under the terms of the previously announced strategic research agreements that Sensyne entered into between November 2020 and January 2021 following completion of a valuation exercise as required under Section 593 of the Companies Act.
Application will be made to the London Stock Exchange for the admission of 5,714,284 New Ordinary Shares to trading on AIM and it is expected that admission will become effective and that dealings will commence at 8.00 a.m. on or around 22 April 2021.
Total Voting Rights
Following the allotment of the New Ordinary Shares to the NHS Trusts, the total number of ordinary shares following admission will be 164,799,139 with each ordinary share carrying the right to one vote. The Company has no shares in Treasury; therefore following admission the total number of voting rights in Sensyne will be 164,799,139. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify an interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 |
Lord (Paul) Drayson PhD FREng, Chief Executive Officer | |
Dr Richard Pye, Chief Financial Officer
| |
Peel Hunt LLP (Nominated Adviser and Joint Broker) |
+ 44 (0) 20 7418 8900 |
Dr Christopher Golden | |
James Steel | |
Victoria Erskine | |
Liberum (Joint Broker) | + 44 (0) 20 3100 2000 |
Bidhi Bhoma | |
Euan Brown | |
Consilium Strategic Communications | +44 (0) 20 3709 5700 |
Mary-Jane Elliott | |
Jessica Hodgson | |
Davide Salvi |
About Sensyne Health:
Sensyne Health plc (LSE: SENS) is a clinical artificial intelligence company operating a unique business model - a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems. The company applies clinical AI in the healthcare and life science industries. In healthcare, Sensyne delivers remote patient monitoring and real time decision making systems for healthcare organizations and their patients. In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information visit www.sensynehealth.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.